Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 7, 2007, Pages 2552-2558

  Joffe, Hylton V ^a   Kwong, Raymond Y ^a   Gerhard Herman, Marie D ^a   Rice, Caitlin ^a   Feldman, Kathryn ^a   Adler, Gail K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; GLUCOSE; HYDROCHLOROTHIAZIDE; MINERALOCORTICOID RECEPTOR; PLACEBO; POTASSIUM; RECEPTOR BLOCKING AGENT;

ALBUMINURIA; AMBULATORY CARE; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; COMMUNITY CARE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DIABETES MELLITUS; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HEART MUSCLE PERFUSION; HUMAN; HYPERTENSION; INTERVENTION STUDY; MALE; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TONOMETRY;

EID: 34447136169     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0393     Document Type: Article

References (40)

1. Prior JO, Quinones MJ, Hernandez-Pampaloni M, Facta AD, Schindler TH, Sayre JW, Hsueh WA, Schelbert HR 2005 Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation 111:2291-2298
2. Pitkanen OP, Nuutila P, Raitakari OT, Ronnemaa T, Koskinen PJ, Iida H, Lehtimaki TJ, Laine HK, Takala T, Viikari JS, Knuuti J 1998 Coronary flow reserve is reduced in young men with IDDM. Diabetes 47:248-254
3. Yokoyama I, Momomura S, Ohtake T, Yonekura K, Nishikawa J, Sasaki Y, Omata M 1997 Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 30:1472-1477
4. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA 2002 Prognostic value of coronary vascular endothelial dysfunction. Circulation 106:653-658
5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M 1998 Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234
6. Hesse B, Meyer C, Nielsen FS, Sato A, Hove JD, Holm S, Bang LE, Kofoed KF, Svendsen TL, Parving HH, Opie LH 2004 Myocardial perfusion in type 2 diabetes with left ventricular hypertrophy: normalisation by acute angiotensin-converting enzyme inhibition. Eur J Nucl Med Mol Imaging 31:362-368
7. Davies JI, Band M, Morris A, Struthers AD 2004 Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 47:1687-1694
8. Sato A, Saruta T 2001 Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 29:13-21
9. Sato A, Hayashi K, Naruse M, Saruta T 2003 Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41:64-68
10. Sato A, Saruta T 2003 Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 16:781-788
11. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717
12. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321
13. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH 2003 Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108:1831-1838
14. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B 2006 Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1:940-951
15. 2006 Standards of medical care in diabetes. Diabetes Care 29:S4-S42
16. Goldstein DE, Little RR, Lorenz RA, Malone JI, Nathan D, Peterson CM, Sacks DB 2004 Tests of glycemia in diabetes. Diabetes Care 27:1761-1773
17. Jerosch-Herold M, Wilke N, Stillman AE 1998 Magnetic resonance quantification of the myocardial perfusion reserve with a Fermi function model for constrained deconvolution. Med Phys 25:73-84
18. Jerosch-Herold M, Swingen C, Seethamraju RT 2002 Myocardial blood flow quantification with MRI by model-independent deconvolution. Med Phys 29:886-897
19. Jerosch-Herold M, Seethamraju RT, Swingen CM, Wilke NM, Stillman AE 2004 Analysis of myocardial perfusion MRI. J Magn Reson Imaging 19:758-770
20. Al-Saadi N, Nagel E, Gross M, Bornstedt A, Schnackenburg B, Klein C, Klimek W, Oswald H, Fleck E 2000 Noninvasive detection of myocardial ischemia from perfusion reserve based on cardiovascular magnetic resonance. Circulation 101:1379-1383
21. McKenzie CA, Pereira RS, Prato FS, Chen Z, Drost DJ 1999 Improved contrast agent bolus tracking using T1 FARM. Magn Reson Med 41:429-435
22. Selvanayagam JB, Jerosch-Herold M, Porto I, Sheridan D, Cheng AS, Petersen SE, Searle N, Channon KM, Banning AP, Neubauer S 2005 Resting myocardial blood flow is impaired in hibernating myocardium: a magnetic resonance study of quantitative perfusion assessment. Circulation 112:3289-3296
23. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS 2002 Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105:539-542
24. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R 2002 Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 39:257-265
25. Bonetti PO, Pumper GM, Higano ST, Holmes Jr DR, Kuvin JT, Lerman A 2004 Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 44:2137-2141
26. Sorensen KE, Celermajer DS, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Thomas O, Deanfield JE 1995 Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility. Br Heart J 74:247-253
27. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ 2003 The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560-2572
28. Pickkers P, Russel FG, Hughes AD, Thien T, Smits P 1995 Hydrochlorothiazide exerts no direct vasoactivity in the human forearm. J Hypertens 13:1833-1836
29. Sihm I, Schroeder AP, Aalkjaer C, Mulvany MJ, Thygesen K, Lederballe O 1998 Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens. Am J Hypertens 11:263-271
30. Wang L, Jerosch-Herold M, Jacobs Jr DR, Shahar E, Folsom AR 2006 Coronary risk factors and myocardial perfusion in asymptomatic adults: the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 47:565-572
31. Janatuinen T, Knuuti J, Toikka JO, Ahotupa M, Nuutila P, Ronnemaa T, Raitakari OT 2004 Effect of pravastatin on low-density lipoprotein oxidation and myocardial perfusion in young adults with type 1 diabetes. Arterioscler Thromb Vasc Biol 24:1303-1308
32. McMahon GT, Plutzky J, Daher E, Bhattacharyya T, Grunberger G, DiCarli MF 2005 Effect of a peroxisome proliferator-activated receptor-γ agonist on myocardial blood flow in type 2 diabetes. Diabetes Care 28:1145-1150
33. Farquharson CA, Struthers AD 2000 Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101:594-597
34. Farquharson CA, Struthers AD 2002 Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 103:425-431
35. Joffe HV, Adler GK 2005 Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 10:31-37
36. Bottcher M, Madsen MM, Refsgaard J, Buus NH, Dorup I, Nielsen TT, Sorensen K 2001 Peripheral flow response to transient arterial forearm occlusion does not reflect myocardial perfusion reserve. Circulation 103:1109-1114
37. Kalliokoski RJ, Kalliokoski KK, Sundell J, Engblom E, Penttinen M, Kantola I, Raitakari OT, Knuuti J, Nuutila P 2005 Impaired myocardial perfusion reserve but preserved peripheral endothelial function in patients with Fabry disease. J Inherit Metab Dis 28:563-573
38. Stolen KQ, Kemppainen J, Kalliokoski KK, Karanko H, Toikka J, Janatuinen T, Raitakari OT, Airaksinen KE, Nuutila P, Knuuti J 2004 Myocardial perfusion reserve and peripheral endothelial function in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 93:64-68
39. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH 2005 Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28:2106-2112
40. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA 2004 Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543-551